This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 4 of 585

BioMarin Shows Up Rival Sarepta During 'JPM15' Investor Presentation

By Adam Feuerstein

Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen.

02:38PM 01/12/15

MannKind Gets Little Love From Sanofi at 'JPM15' Presentation

By Adam Feuerstein

The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.

01:35PM 01/12/15

Celgene Has 2020 Vision for Long-Term Growth but Plays Safe for 2017

By Adam Feuerstein

Celgene CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.

11:40AM 01/12/15

Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

By Adam Feuerstein

The company presents at the J.P. Morgan Healthcare Conference on Thursday.

09:47AM 01/12/15

Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival

By Adam Feuerstein

Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.

07:07AM 01/12/15

Vertex Pharma To Start Next-Gen Cystic Fibrosis Drug Studies Earlier Than Expected

By Adam Feuerstein

The company announced its 2015 business outlook on Sunday ahead of its presentation at the J.P. Morgan Healthcare Conference.

06:08AM 01/12/15

Roche to Acquire Majority Stake in Cancer Genetic Test Maker Foundation Medicine

By Adam Feuerstein

Roche's $1 billion-plus investment in Foundation Medicine aims to expand use of genetic testing to develop new, more effective drugs.

01:00AM 01/12/15

Tale of 2 Rare Disease Stocks: Aegerion, NPS Pharmaceuticals

By Adam Feuerstein

A successful rare-disease drug launch and the development of a second product made NPS an attractive takeout target.

12:15AM 01/12/15

Gilead, Express Scripts May Be Movers Next Week Amid Healthcare Conference

By Adam Feuerstein

TheStreet senior columnist Adam Feuerstein previews what to watch at the J.P. Morgan Healthcare Conference, which kicks off Monday in San Francisco.

03:11PM 01/09/15

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab

By Adam Feuerstein

Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.

02:56PM 01/09/15

Page 4 of 585

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs